Cited 0 times in Scipus Cited Count

Alpha-fetoprotein-producing gastric cancer.

DC Field Value Language
dc.contributor.authorLee, R-
dc.contributor.authorRha, SY-
dc.contributor.authorAhn, JB-
dc.contributor.authorShim, KY-
dc.contributor.authorChoi, JH-
dc.contributor.authorLim, HY-
dc.contributor.authorYoo, NC-
dc.contributor.authorNoh, SH-
dc.contributor.authorKim, JH-
dc.contributor.authorRoh, JK-
dc.contributor.authorMin, JS-
dc.contributor.authorKim, BS-
dc.contributor.authorChung, HC-
dc.date.accessioned2011-09-06T06:47:52Z-
dc.date.available2011-09-06T06:47:52Z-
dc.date.issued1998-
dc.identifier.issn1021-335X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/4049-
dc.description.abstractWe measured the sero-positivity rate of serum alpha-fetoprotein (alphaFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis. The sero-positive rate was 9.8% (8/82) and the positivity increased with cancer progression. Sex, age and pathological type were similar between alphaFP-positive and -negative patients. The overall synchronous hepatic metastasis rates in alphaFP-positive and alphaFP-negative groups were 37.5% (3/8) and 12.2% (9/74), respectively (p=0.08). The predictability of synchronous liver metastasis in eight alphaFP-positive patients were as follows: 37. 5% of total patients (3/8), 50.0% (3/6) of unresectable patients, and 60.0% (3/5) of patients with systemic metastasis. In three alphaFP-positive patient with liver metastasis, all the hepatic lesions were intrahepatic and multiple, while in alphaFP-negative patients, 67% (6/9) of the hepatic lesions was single intrahepatic lesion or surface nodule. The predictability of both synchronous and metachronous liver metastasis in alphaFP-positive gastric cancer patients was 75%. These findings suggested that, in advanced stomach cancer patients, especially in stage IV, alphaFP can be used in predicting liver metastasis during follow-up.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHPalliative Care-
dc.subject.MESHPrognosis-
dc.subject.MESHStomach Neoplasms-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.subject.MESHalpha-Fetoproteins-
dc.titleAlpha-fetoprotein-producing gastric cancer.-
dc.typeArticle-
dc.identifier.pmid9683831-
dc.identifier.urlhttp://www.spandidos-publications.com/or/5/5/1179-
dc.contributor.affiliatedAuthor최, 진혁-
dc.contributor.affiliatedAuthor임, 호영-
dc.type.localJournal Papers-
dc.citation.titleOncology reports-
dc.citation.volume5-
dc.citation.number5-
dc.citation.date1998-
dc.citation.startPage1179-
dc.citation.endPage1184-
dc.identifier.bibliographicCitationOncology reports, 5(5). : 1179-1184, 1998-
dc.identifier.eissn1791-2431-
dc.relation.journalidJ01021335X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse